A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC.

Jaejun LeePil-Soo SungHyun YangSoon Kyu LeeHee Chul NamSun Hong YooHae Lim LeeHee Yeon KimSung Won LeeJung Hyun KwonJeong Won JangChang Wook KimSoon Woo NamSi Hyun BaeJong Young ChoiSeung Kew Yoon

Published in: Journal of clinical medicine (2020)

In this real-world study, lenvatinib was demonstrated to be more efficacious than sorafenib as a salvage therapy for transarterial treatments in unresectable HCC.

Keyphrases

liver metastases
locally advanced